AT2k Design BBS Message Area
Casually read the BBS message area using an easy to use interface. Messages are categorized exactly like they are on the BBS. You may post new messages or reply to existing messages!

You are not logged in. Login here for full access privileges.

Previous Message | Next Message | Back to Engadget is a web magazine with...  <--  <--- Return to Home Page
   Local Database  Engadget is a web magazine with...   [120 / 153] RSS
 From   To   Subject   Date/Time 
Message   VRSS    All   The FDA approves human trials for pig kidney transplants   September 9, 2025
 11:54 AM  

Feed: Engadget is a web magazine with obsessive daily coverage of everything new in gadgets and consumer electronics
Feed Link: https://www.engadget.com/
---

Title: The FDA approves human trials for pig kidney transplants

Date: Tue, 09 Sep 2025 16:54:16 +0000
Link: https://www.engadget.com/science/the-fda-appr...

Despite how it sounds, a xenotransplant isn't something from the latest Alien
movie. It's an increasingly credible science: the transplantation of animal
organs into humans. The field took one of its biggest leaps forward on
Monday. The FDA approved the biotech company eGenesis to begin human trials
of pig-to-human kidney transplants.

eGenesis provides pigs with CRISPR-modified genes. These genetic changes
reduce the chances of organ rejection in human recipients. The FDA approved
the company for Investigational New Drug (IND) Clearance for a three-phase
study. Each stage will increase the number of patients if the results support
moving forward.

Only those with end-stage kidney disease will be eligible. They'll also need
to be 50 or older, dialysis-dependent and on the kidney transplant waitlist.
Around 86,000 people are currently on the kidney waitlist. The average wait
time is three to five years at most centers. It can be longer for rarer blood
types. Over 800,000 Americans have end-stage kidney disease.

eGenesis isn't alone: United Therapeutics, another gene-edited pig developer,
will soon begin enrolling people in a similar FDA-approved study.

"Advances in xenotransplantation are giving our community hope that new
options may soon be available to those who need them most," National Kidney
Foundation CEO Kevin Longino wrote in a press release. "Patients expressed
strong support for the advancement of clinical trials in our recent
Xenotransplantation Voice of the Patient report. It is gratifying to know
they're being heard."

The trial approval coincided with news of another successful xenotransplant.
Bill Stewart, an otherwise healthy 54-year-old New Hampshire resident,
received one of eGenesis' pig kidneys on June 14. Before the operation, he
received dialysis three times per week for over two years. His organ donor
wait was longer than most due to his blood type. He was discharged from
Massachusetts General Hospital on June 21 and no longer requires dialysis.

"There's so few of us who have done this, and they're writing the protocol as
we go, so to speak," Stewart told CNN. "But I'm feeling good."

Tim Andrews, 67, received a pig kidney in January. Before his transplant, he
required dialysis for over two years. Over seven months after the operation,
he's still dialysis-free. He's currently the longest living recipient.

Earlier transplant recipients had significant underlying health problems.
That limited scientists' ability to conduct long-term tests. Trials with
healthier patients will assess the durability of the organs over time.

This article originally appeared on Engadget at
https://www.engadget.com/science/the-fda-appr...
transplants-165416004.html?src=rss

---
VRSS v2.1.180528
  Show ANSI Codes | Hide BBCodes | Show Color Codes | Hide Encoding | Hide HTML Tags | Show Routing
Previous Message | Next Message | Back to Engadget is a web magazine with...  <--  <--- Return to Home Page

VADV-PHP
Execution Time: 0.0135 seconds

If you experience any problems with this website or need help, contact the webmaster.
VADV-PHP Copyright © 2002-2025 Steve Winn, Aspect Technologies. All Rights Reserved.
Virtual Advanced Copyright © 1995-1997 Roland De Graaf.
v2.1.250224